The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | The safety and efficacy of venetoclax-based treatment for patients with Richter’s syndrome
Paul Hampel, MD, Mayo Clinic, Rochester, MN, discusses the safety and efficacy of venetoclax-based treatment for patients with Richter’s syndrome. Dr Hampel first provides some background information on Richter’s syndrome and the poor outcomes associated with these patients, and then further discusses the promising activity observed with a variety of venetoclax-based regimens. Following this, Dr Hampel highlights the safety profile of these combinations and the importance of further investigating their efficacy. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
